SFEBES2007 Poster Presentations AMEND Young Investigator's Award (21 abstracts)
Testicular teratoma, testicular seminoma and papillary thyroid carcinoma occurring in a single individual: a report of two unrelated cases
Akheel A Syed 1 , Nigel AG Jones 2 , J Trevor Roberts 3 , Ujjal K Mallick 3 , Fiona Douglas 4 , Petros Perros 1 & Richard Quinton 1
1Newcastle University Teaching Hospitals, Newcastle upon Tyne, United Kingdom; 2Freeman Hospital, Newcastle upon Tyne, United Kingdom; 3Northern Centre for Cancer Treatment, Newcastle upon Tyne, United Kingdom; 4Clinical Genetics, Centre for Life, Newcastle upon Tyne, United Kingdom.
We describe two unrelated men with a previously unreported combination of tumours. The first patient developed a right-sided testicular teratoma at the age of 25 years treated with orchidectomy. He went on to develop a left-sided seminoma at the age of 35 years, treated with orchidectomy followed by prophylactic para-aortic radiotherapy (30 Gy in 15 fractions). At the age of 48 years he developed a nodule in the left lobe of thyroid (AC4/Thy4 on FNA) treated with hemithyroidectomy followed by completion thyroidectomy for papillary carcinoma of the thyroid (pT4 Nx M0), followed by ablative radioiodine therapy (3700 MBq). The second patient developed a right-sided intermediate grade malignant testicular teratoma at the age of 19 years treated with radical orchidectomy. At that time biopsy from the left testis was normal with active spermatogenesis, but he subsequently developed a left-sided testicular seminoma with extensive intratubular germ cell neoplasia at the age of 25 years. This was also treated with radical orchidectomy after sperm storage, but radiotherapy was not deemed to be necessary. A year later he developed a solitary thyroid nodule (AC3 on FNA), treated with hemithyroidectomy and completion thyroidectomy for multifocal follicular variant of papillary carcinoma (pT2 Nx Mx), followed by ablative radioiodine therapy (3030 MBq). Neither patient had a family history of cancers. Both remain well on testosterone and thyroxine replacement with no evidence of tumour recurrence on continued surveillance. Random occurrence is a possible explanation for this previously unreported combination of tumours. However, an as yet undiscovered genetic predisposition (or environmental influence or both) would seem rather more likely.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more